Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Aug;36(8):2317-23.
doi: 10.2337/dc12-2521. Epub 2013 Mar 20.

Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects

Maria F Lopes-Virella  1 , Nathaniel L Baker, Kelly J Hunt, Patricia A Cleary, Richard Klein, Gabriel Virella; DCCT/EDIC Research Group
Collaborators, Affiliations
Randomized Controlled Trial

Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects

Maria F Lopes-Virella et al. Diabetes Care. 2013 Aug.

Abstract

Objective: The current study aimed to determine in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications cohort whether or not abnormal levels of markers of inflammation and endothelial dysfunction measured in samples collected at DCCT baseline were able to predict the development of macroalbuminuria.

Research design and methods: Levels of inflammation and endothelial cell dysfunction biomarkers were measured in 1,237 of 1,441 patients enrolled in the DCCT study who were both free of albuminuria and cardiovascular disease at baseline. To test the association of log-transformed biomarkers with albuminuria, generalized logistic regression models were used to quantify the association of increased levels of biomarkers and development of abnormal albuminuria. Normal, micro-, and macroalbuminuria were the outcomes of interest.

Results: In the logistic regression models adjusted by DCCT treatment assignment, baseline albumin excretion rate, and use of ACE/angiotensin receptor blocker drugs, one unit increase in the standardized levels of soluble E-selectin (sE-selectin) was associated with an 87% increase in the odds to develop macroalbuminuria and one unit increase in the levels of interleukin-6 (IL-6), plasminogen activator inhibitor 1 (PAI-1; total and active), and soluble tumor necrosis factor receptors (TNFR)-1 and -2 lead to a 30-50% increase in the odds to develop macroalbuminuria. Following adjustment for DCCT baseline retinopathy status, age, sex, HbA1c, and duration of diabetes, significant associations remained for sE-selectin and TNFR-1 and -2 but not for IL-6 or PAI-1.

Conclusions: Our study indicates that high levels of inflammatory markers, mainly E-selectin and sTNRF-1 and -2, are important predictors of macroalbuminuria in patients with type 1 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of progression to macroalbuminuria for high (upper quartile) versus low (lower quartiles) for sE-selectin (A), sTNFR-1 (B), and sTNFR-2 (C).
See this image and copyright information in PMC

Comment in

References

    1. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 2003;18:1716–1725 - PubMed
    1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986 - PubMed
    1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl. 1):S1–S266 - PubMed
    1. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987;31:673–689 - PubMed
    1. Viberti GC, Jarrett RJ, Keen H. Microalbuminuria as prediction of nephropathy in diabetics. Lancet 1982;2:611. - PubMed

Publication types